Genomics and circulating biomarkers
The research is focused on implementation of complex genomic analyses of the liquid biopsy (circulating tumor cells, circulating tumor DNA, extracellular vesicles, free circulating biomarkers) in the diagnosis, follow-up and therapy of cancer patients. The minimal invasiveness and repeated samplings of liquid biopsy provides accurate and actual information about the current extent of the disease, the effect of therapy or the disease recurrence, thus enabling targeted treatment at the right time. The group members were engaged in translational research in the field of liquid cancer biopsy for more than 15 years and established several diagnostic methods to predict dissemination and/or progression of human cancer.
- Cancer genomics
- Gene expression and regulation in cancer
- Liquid biopsy
- Circulating tumor cells
- Rare diseases
Optimization of genomic methods in the cancer diagnostics using liquid biopsy. The methodological procedures are crucial for handling with small amount of biological material and need to be optimized. Especially, for analysis of circulating tumor cells and circulating free tumor DNA, the purification, amplification and library preparation steps seem to be fundamental for high quality results. Validation of novel circulating biomarkers. The main research area is identification and validation of novel diagnostic, prognostic and predictive biomarkers in cancer using non-invasive liquid biopsy. The Srovnal’s group is focused on both, circulating tumor cells and plasmatic biomarkers detection in colorectal cancer, pancreatic cancer, breast cancer and lung cancer since 2005. Currently, the effect of opioid drugs on cancer dissemination is in the spotlight.